
Liver-chip validation: the evidence and investment gate for a NAM
FDA’s 2026 terminology change, a historical liver-chip benchmark and a transparent error-cost model show what a validation investment must establish.
READING, IN ANOTHER FORM
Start with the founding collection: one article from each pillar. Monthly sets will rotate when volumes are released.
17 min · Bella
17 min · Bella
15 min · Hermione
12 min · Hermione
From discovery to clinical evidence. Understand what a result establishes, and what remains uncertain.

FDA’s 2026 terminology change, a historical liver-chip benchmark and a transparent error-cost model show what a validation investment must establish.
The Elevidys safety revision informs a hypothetical surveillance budget and an eligibility-sensitive operating plan.
Leqembi’s randomized evidence and AMT-130’s September update frame a client’s sensitivity analysis and evidence reserve.

A new antibiotic can be most valuable when it is used carefully. That creates a revealing challenge for how we fund discovery, protect effectiveness, and keep treatment available.
4 min read
The platforms that turn biological potential into practical medicines and devices.

Vyxeos provides the clinical anchor; a separate yield and cash-cost model tests whether a manufacturing improvement deserves investment.
SYMPLICITY HTN-3 frames a hypothetical device trial budget, site plan and milestone gate.
Genzyme’s remediation history anchors a hypothetical outage-exposure and backup-capacity decision.

Living cells and carefully engineered channels offer a new window into human biology. The important question is which part of an organ a tiny model can faithfully represent.
4 min read
How promising science reaches people: scale, economics, adoption, and access.

A patient-pathway funnel, starter-dose capacity check and financial threshold show why convenient dosing still needs an operating system.
Recent generic-pressure reporting anchors a fictional sales-force redeployment and productivity model.
Wegovy’s outcomes result and Medicare’s next negotiation cycle frame evidence, budget and eligible-population planning.

A result can move in the right direction while a person’s daily life remains difficult. Patient-reported outcomes help research ask more precisely what improvement means.
4 min read
Connect evidence, access, execution, and capital around the next decision that matters.

Merck–Moderna’s collaboration provides the timeline; a separate cash model tests option exercise, delay, settlement and the no-payment branch.
The CRISPR patent appeal frames a hypothetical rights map, licensing sensitivity and IP diligence gate.
A development-stage acquisition and a company-reported upcoming review date frame a fictional option-value model.
From discovery to clinical evidence. Understand what a result establishes, and what remains uncertain.